Delivery Order SPE2DB22D9239-SPE2DB25FDD72

Award Date 10/8/24
Potential Completion Date 10/30/24
Potential Value $34K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,764.88 firm fixed-price delivery order is for the supply of Perjeta 420 mg/14 ml vial (14 ml) to fulfill the recurring medical supply needs of military health facilities. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the...
This federal contract award is a delivery order valued at $13,671.78 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Perjeta, a 420 mg/14 ml vial medication, with a period of performance through April 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This federal contract award was made by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $34,039.68 firm fixed-price delivery order is for the supply of Perjeta 420 mg/14 ml vials, a specialty oncology medication. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $87,087.84, is a firm fixed-price delivery order for the supply of 420 mg/14 ml vials of the drug Perjeta. The contract has an ultimate completion date of August 18, 2021. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the...
The federal contract award, valued at $25,529.76, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This is a delivery order awarded under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. The IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive...
This federal contract award was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,509.92 firm fixed-price delivery order is for the supply of 420 mg/14 mL vials of the oncology drug Perjeta. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA, under the SPE2DB program, that allows...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $34,039.68, is for the delivery of Perjeta 420 mg/14 ml vial, a branded oncology medication, with a performance period ending on July 3, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,529.76 firm fixed-price delivery order is for the supply of Perjeta 420 mg/14 ml vials to fulfill the medical needs of U.S. military personnel and their dependents. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) under the DLA's SPE2DB program, which allows the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,509.92 firm fixed-price delivery order is for the supply of 4,566,708,650 units of the drug Perjeta (420 mg/14 ml vial) with a completion date of January 2, 2025. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $14,514.64, is a firm fixed-price delivery order for the supply of the drug Perjeta (420 mg/14 ml vial). DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB25FDD72
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $34,039.68 firm fixed-price delivery order is for the supply of Perjeta 420 mg/14 ml vials, with a period of performance through October 30, 2024.

DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This single-award IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation.

Generated 1/7/25, 11:46 AM